相关实验视频
Updated: Jul 10, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.9K
使用CGM来识别先天性高胰岛素症中的低血糖和血糖模式
Martin Gariepy1, Niyoosha Yoosefi1, Carolina Silva2
1Department of Pediatrics, University of British Columbia, Vancouver, Canada.
Journal of pediatric endocrinology & metabolism : JPEM
|November 21, 2023
概括
持续血糖监测 (CGM) 在患有先天性高胰岛素症 (HI) 的儿童中检测到以前未被识别的低血糖症. 这项技术有助于识别葡萄糖模式,并指导治疗调整以获得更好的血糖控制.
科学领域:
- 儿科内分泌学 儿科内分泌学
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 先天性高胰岛素症 (HI) 带来低血糖和不良神经结果的风险,特别是在新生儿中.
- 护理点检测 (POCT) 是HI的标准,但持续血糖监测 (CGM) 在其他儿科糖尿病人群中显示出希望.
- 关于在患有HI的儿童中使用CGM的数据有限.
研究的目的:
- 为了评估稳定治疗HI的儿童的血糖模式.
- 在这个人群中使用Dexcom G6® CGM来确定未检测到的低血糖的频率.
主要方法:
- 一项试点观察性研究,涉及10名被诊断为HI的儿童 (3个月至17岁),接受稳定的药物治疗.
- 参与者使用了标准的POCT,并在20天内戴着一个失明的Dexcom G6® CGM.
- 在严重低血糖的情况下,有可能揭示CGM数据.
主要成果:
- 在60%的参与者中,CGM确定了26次低血糖事件.
- 显著的一部分低血糖 (45%) 发生在0600和0800之间.
- 根据CGM发现,对30%的研究人群进行了药物剂量调整.
结论:
- CGM有效地检测低血糖和葡萄糖趋势,特别是在没有POCT的时期.
- 这些数据可以为HI儿童的医疗管理和药物调整提供信息.
- 该研究的小样本大小限制了概括性.
相关概念视频
Hypoglycemia and Glucagon
273
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
273
Diabetes Mellitus: Type 2 and Gestational
2.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K
Diabetes Mellitus: Overview and Type I Subtype
2.7K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.7K
Hormones Regulating Blood Glucose
3.4K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.4K
Pathophysiology of Diabetes
950
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
950
Oral Hypoglycemic Agents: Glinides
157
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
157

